The association of the severity of liver disease and the molecular evolution of hepatitis C virus (HCV) during chronic infection remains unclear and controversial. To address this we have studied the interpatient variability in the nucleotide sequence of two regions of the HCV genome, E1/E2, which contain the hypervariable region 1 and the nonstructural NS5b region, in a cohort of Irish female patients who were all recipients of a single source of HCV genotype 1b-contaminated anti-D immunoglobulin in 1977 and 1978 and who over the subsequent 20 years developed a spectrum of liver disease. In addition, quasispecies analysis was used to evaluate intrapatient variability in the E1/E2 region in four patients with mild and four with severe disease. Phylogenetic and evolutionary rate analyses of the nucleotide sequences demonstrated that there was no significant difference between those who developed mild disease and those who had progressed to severe disease or cirrhosis. These findings suggest that other factors, either additional viral or host, may be important in the pathogenesis and clinical outcome of chronic hepatitis C virus infection. © 2002 Elsevier Science (USA)
INTRODUCTION
Hepatitis C virus (HCV) contains a positive-strand RNA genome of approximately 9.6 kb in molecular weight that encodes a polyprotein of approximately 3010 amino acids (Choo et al., 1991) . HCV, of which there are a number of distinct genotypes, is similar to a number of other RNA viruses, in that it exhibits a high degree of genetic heterogeneity both within and between infected individuals . The viral genome contains a highly conserved region, the 5Ј untranslated region (5ЈUTR) (Choo et al., 1991) , and regions which display moderate variability, including the core and nonstructural (NS) regions (Weiner et al., 1991; Bukh et al., 1993) . The greatest degree of heterogeneity has been observed in the N-terminal of the envelope-encoding region, E2 (Weiner et al., 1991; Weiner et al., 1992; Kato et al., 1993) , and this has been designated the hypervariable region 1 (HVR1). The HVR1 has been reported to exhibit a three to four times higher rate of variation over time than nonstructural regions in persistently infected individuals (Okamoto et al., 1992) .
Biological and molecular studies have suggested that the evolution of and changes in the nucleotide sequence of the HVR1 allows the development of escape mutants and consequently the establishment of persistent infections and a chronic carrier state (Farci et al., 2000; Higashi et al., 1993; Ray et al., 1999; Van Doorn et al., 1995) . However, the association between the evolution of genetic heterogeneity and the clinical features of infection, specifically the severity of liver disease, remains controversial. While a number of studies have suggested a correlation between the degree of sequence diversity in the HVR1 and the development of severe liver disease (Honda et al., 1994; Koizumi et al., 1995; Curran et al., 2002) , these findings have not been confirmed by others (Naito et al., 1995) . The major limitations of these studies are that they have involved analyses of different populations infected with different virus genotypes, often for different and even unknown time periods, where there have been variable sources of infection. In an attempt to resolve this question we have analyzed a population of Irish females who were infected from a single source of HCV, genotype 1b-contaminated anti-D immunoglobulin, in 1977 HCV, genotype 1b-contaminated anti-D immunoglobulin, in -1978 , and who in the subsequent 20-year period have developed a spectrum of liver disease (KennyWalshe, 1999) . Specifically, nucleotide sequence, phylogenetic analysis, and rates of evolution of the E1/E2 region which included the HVR1 and the nonstructural NS5b region were compared in individuals with severe disease to those in individuals with mild or no disease.
RESULTS

Nucleotide sequence and phylogenetic analysis
The neighbor joining (NJ) tree for HVRtot (anti-D and unrelated E1/E2 sequences) with bootstrap supports is shown in Fig. 1 . The anti-D cohort was found to cluster with HCV 1b (Fig. 1 ) with bootstrap support of 100%. On the HVRds (anti-D and published unrelated HCV 1b E1/E2 sequences) NJ (Fig. 2) , the anti-D cohort was found to cluster distinctly from the published and unrelated HCV 1b sequence of the E1/E2 region with a bootstrap support of 96%, suggesting that this represents a unique genotype 1b clade. Included within this group are the E1/E2 sequences previously reported for other Irish patients infected with the same contaminated anti-D product collected in 1994 (AF056789, AF056792, AF056794, AF056790, AF056791, AF056745, AF056736, AF056748, AF056751, AF056752) (McAllister et al., 1998) . However, no clinical or histological information is available on these patients. The phylogenetic analysis of our patient population clearly demonstrated that there was no distinct clustering of sequences from patients with high (underlined in Fig. 2 ) and low fibrotic scores (other R sequences). Phylogenetic analysis of the NS5b region of our population (data not shown) gave similar findings; however, in contrast to the E1/E2 region, there was no support (bootstrap value 36%) in the analysis for considering the anti-D cohort as a distinct clade. This is probably due to the low phylogenetic signal in the NS5b region (Salemi and Vandamme, 2002) . Nucleotide sequences of the aforementioned 1994 collection have not been included since they are only 222 bp in length (Power et al., 1995) Amino acid variation within the NS5b and HVR1
The 20 NS5b nucleotide sequences of the anti-D cohort had only a total of 8 amino acid substitutions over 99 amino acids for the 20 isolates (data not shown). The E1/E2 nucleotide sequences for the anti-D cohort had most nonsynonymous substitutions concentrated in the HVR1. Table 1 illustrates the variation within the HVR1 region at the amino acid level. All sequences were compared with that present in the original infective batch, AF056736 (McAllister et al., 1998) . Overall, there was an average change of 26% in the 31 amino acids. Patients with a high fibrotic score had a variation of 24.9% while those with a low fibrotic score had a variation of 26.7%, demonstrating that there is no significant difference between patients with mild and severe disease (P ϭ 0.395 in a two-tailed t test). Five sites (amino acids 6, 20, 24, 25, and 31) were found to be consistently conserved, which is in agreement with a previous report (McAllister et al., 1998) . In the majority of positions, the amino acid changes observed were restricted to two to four variants with conserved characteristics. These results agree with previous studies (Puntoriero et al., 1998; Sobolev et al., 2000; Penin et al., 2001) , suggesting that the amino acid substitutions in this region do not occur in a random fashion and that there is some constraint on the changes within the HVR1.
Evolutionary rate analysis
In order to calculate an evolutionary rate for a set of nucleotide sequences, the data must be analyzed for the presence of a molecular clock to determine whether they have evolved at a constant rate. When the E1/E2 nucleotide sequences were analyzed in TREE-PUZZLE, the log likelihood of the more complex (no clock) tree was significantly better than that from the clock tree. Since the presence of a molecular clock was rejected, an evolutionary rate had to be calculated individually for each patient by counting the total number of substitutions between the donor material (represented by AF056736) and the current patient sequence. The evolutionary rate was calculated for the E1/E2 nucleotide sequence of each patient (Fig. 3) . However, using a two-tailed t test, 
FIG. 2.
The neighbor joining tree for the 364 nucleotides of the E1/E2 (HVRds) alignment with 1000 bootstraps. Bootstrap support is given in the percentage along the relevant branch. The outgroup, HCU14239, is an unrelated HCV 1b sequence. The anti-D cohort forms a distinct cluster compared to unrelated HCV 1b sequences, with a bootstrap support of 96%; the sequences from this study are in boldface while those from the anti-D cohort, compiled in Edinburgh, Scotland, in 1994 (McAllister et al., 1998 , are in plain type. The sequences from the contaminated source of anti-D are highlighted as the archival sample, while the 1998 sequence individual is R29217 (*). The sequences from the patients with high fibrosis scores are underlined. no significant difference was found in evolutionary rates between patients with mild disease and those with severe disease (P ϭ 0.2682). The average evolutionary rate of patients with mild disease was 2.23 ϫ 10 Ϫ3 nucleotide substitutions/site/year and those with severe disease was 2.22 ϫ 10 Ϫ3 nucleotide substitutions/site/year.
Quasispecies analysis
To investigate the intrapatient variability in the E1/E2 region, four patients with mild disease, R29217, R35041, R35016, and R35060, and four patients with severe disease, R35044, R35028, R35076, and R35047, were selected for further analysis. The E1/E2 PCR fragment was cloned, and 9-13 clones were sequenced to provide a representation of the quasispecies present within these patients. All sequences were included in the phylogenetic analysis (HVRquasi) (Fig. 4) . As expected, a distinct clustering, with high bootstrap support, of the sequences from R35044 (99.1%), R35047 (73.1%), R35060 (94.7%), R35041 (85.9%), R35076 (94.6%), R35028 (75.3%), R35016 (93.2%), and R29217 (98.0%) was observed. The rate of variability within each patient was also investigated (Table 2), and while the molecular clock hypothesis can be supported for R35016, R35028, and R35076 and an evolutionary rate can be calculated, there is no support for the molecular clock in the other patients.
VESPA analysis
The predicted amino acid sequences of the E1/E2 region were divided into two sets, one representing the sequences from the 13 patients with no fibrosis or mild disease and the other containing those from patients with severe disease or cirrhosis. Using the VESPA program with a threshold value of 0.80 to search for signature patterns that might be associated with disease pro- The 31-Amino-Acid Sequence of the HVR1 Note. All sequences have been compared to the predicted amino acid sequence of AF056736 (McAllister et al., 1998) , a sequence obtained from the infective source of HCV for this cohort. R29217 is the 1998 sample from the original donor from which the anti-D product was manufactured. The 6 sequences at the bottom of the table have high HAI scores (3-4) for stage of disease.
FIG. 3.
The evolutionary rate (nucleotide substitutions/site/year) of the E1/E2 nucleotide region of each patient versus their HAI staging score indicates that there is no significant difference (P ϭ 0.2682) in the rate of evolution between those patients with mild disease (0-1) and those with severe disease (3-4).
gression, no such pattern was identified. A similar analysis was also carried out with the quasispecies and, while patterns could be identified within individual patients, no signature amino acid patterns could be identified in those with severe disease or cirrhosis compared to those with no fibrosis or mild disease.
FIG. 4.
Neighbor joining bootstrap consensus tree (1000 replicates) of HCV quasispecies, using 364 nucleotides of the E1/E2 region from four patients with mild disease, R29217, R35041, R35016, and R35060, and four patients with severe disease, R35044, R35028, R35076, and R35047. The patients were infected by a single source of HCV genotype 1b-contaminated anti-D immunoglobulin (see Materials and Methods). The original HCV donor sequence was used as the outgroup.
DISCUSSION
The relationship of the progression and the severity of liver disease and the molecular evolution of HCV in chronic infection remains controversial. In the present study we have taken advantage of an unfortunate event in which a large population of Irish females was infected from a single source of HCV genotype 1b (with a similar inoculum size which contained a homogeneous virus population) and who have developed a spectrum of liver disease over a clearly defined time period to investigate whether there is an association between the development of disease and nucleotide sequence variation. Specifically, phylogenetic and evolutionary rate analysis was employed to analyze the inter-and intrapatient diversity and evolution of the nucleotide sequences in the E1/E2 and NS5b regions of the virus genome.
Phylogenetic analysis of the E1/E2 region including the HVR1 suggested that the viruses in this population formed a separate clade distinct from that of the HCV genotype 1b of other origins. However, this was not supported in the analysis of the NS5b region, and while the reasons are unclear, this is likely related to differences in the rates of evolution of the nucleotide sequences in the two regions. Most of the amino acid changes in the HVR1 appeared to be restricted to amino acids with conserved biochemical properties, suggesting that variation in this region is somewhat restricted and appears not to occur randomly. Overall, our studies clearly show that there is little difference in the nucleotide or amino acid variation in the investigated gene regions between the 13 patients with no to mild fibrosis and the 6 with severe fibrosis or cirrhosis.
One limitation of our study was that only selected regions representing a small part of the entire genome have been analyzed and it is thus possible that there could be sequence variation in other regions that might correlate with the progression of liver disease. Further detailed and extensive sequence analysis will be required to resolve this. Our findings, however, clearly support the apparent lack of association between the extent of genetic heterogeneity of the HVR1 and the severity of the liver disease. A previous study involving hypogammaglobulinemic patients has shown that the induction and selection of mutants in the HVR1 appears not to be necessary for the development of cirrhosis (Taniguchi et al., 1993) . The observation that our patient population, which presumably has intact immune systems, also displayed variability in the HVR1, which would presumably also allow the development of escape mutants and persistent infections, suggests that other factors must be involved in the development of severe liver disease. This view is also supported by one report which showed no association between the development of increased diversity in the HCV quasispecies and the Knodell biopsy scores (Gonzalez-Peralta et al., 1996) . Another study involving chimpanzees infected with wildtype HCV not containing 81 nucleotides of the HVR1 indicated that these nucleotides appeared not to be essential for the viability of the virus, resolution of infection, or development of chronicity (Forns et al., 2000) .
The evolutionary rate analysis in this present study has allowed an accurate estimation of the number of nucleotide substitutions/site/year for each patient. This ranged from 2.73 ϫ 10 Ϫ3 to 1.53 ϫ 10 Ϫ3 , and there was no difference in the evolutionary rate between patients with severe and mild disease in the E1/E2 region examined. The estimates of evolutionary rates are in close agreement with a previous study (Salemi et al., 2001 ). Unfortunately, it is not possible to draw any conclusions about intrapatient quasispecies variability and a correlation , 1999) . c Transition transversion ratio and ␣-shape parameter of the ⌫-distribution (only for models allowing ⌫-distributed rates across sites) were estimated via maximum likelihood by TREE-PUZZLE 5.0 (Strimmer and Von Haeseler, 1997) .
d The molecular clock hypothesis was evaluated with the likelihood ratio test implemented in TREE-PUZZLE 5.0. The molecular clock is not rejected when P Ͼ 0.05.
with disease state, as it was only possible to calculate an evolutionary rate for one patient (R35016) with mild and two patients (R35028 and R35076) with severe disease. We also attempted to establish whether there were differences in the evolutionary rates of the E1/E2 of the virus in our cohort with genotype 1b sequences available in the database with known time frames of infection. However, the latter studies are extremely limited. On the basis of an analysis of sequences obtained over a known time frame from a study by Enomoto et al. (1995) on one Japanese patient, we have estimated a rate of 1.0 ϫ 10 Ϫ1 nucleotide substitutions per site per year for E1/E2. If this is correct, then there is at least a 100-fold difference in the rate of evolution compared to that in our anti-D cohort. However, this study involved the analysis of only one patient before and then some 26 weeks following interferon treatment. This is a relatively short period of time compared to our study and may have been confounded by the institution of antiviral therapy. Moreover, it is unknown how long this patient may have been infected prior to the initiation of the study. It is also unclear whether the obviously different genetic backgrounds of the patients could contribute to the differences in the evolutionary rates. Another estimate of the rate of evolution in the E1/E2 region was calculated for sequences obtained 9 years apart (Abe et al., 1995) , where a rate of 1.5 ϫ 10 Ϫ3 nucleotide substitutions per site per year was calculated. While this is within the range found for our cohort, a comparison of these two studies is limited, as the initial sequence was from a sample collected from an infected patient, whereas the follow-up sample was from a chimpanzee infected with the same patient's plasma. Sequences from a further study investigating E1/E2 variability over a period of 11 months in a Japanese patient, beginning 3 years after a nonresponse to interferon therapy, calculated a rate of 3.1 ϫ 10 Ϫ2 nucleotide substitutions per site per year. However, a direct comparison with our study is difficult in that the nucleotide sequences analyzed were from a different region of the viral genome. An average rate of 8.59 ϫ 10 Ϫ2 nucleotide substitutions per site per year for the 81 nucleotides of the HVR was calculated from a study of five patients with samples taken 1-6 years apart (Booth et al., 1998) ; however, the duration of infection and the HCV genotype(s) involved are unknown. Another study of 200 nucleotides (Christie et al., 1999) , 197 of which are included in our study, indicated a rate of 2.38 ϫ 10 Ϫ2 nucleotide substitutions per site per year, with the three patients infected with HCV genotype 1a within 5 years of the study and the samples taken 2 years apart.
In conclusion, our study has permitted an accurate analysis of the rates of evolution of nucleotide sequences during chronic genotype 1b HCV infection in the E1/E2 region at a single time point 20 years after initial infection. While viral quasispecies complexity can predict clearance or persistence of infection (Farci et al., 2000; Ray et al., 1999) , this study has clearly demonstrated that there appears to be no correlation between the degree of genetic variability or heterogeneity in the regions of the HCV genome studied and the clinical and histological features of infection. This suggests that either other viral factors, perhaps involving other gene regions, may play an important role or possibly that host factors are extremely important. In this regard, it has been reported that human leukocyte antigen Class II alleles may be important contributors to disease outcome in the Irish cohort (Fanning et al., 2001) and to persistence of the virus (Barrett et al., 1999; Cramp et al., 1998; Fanning et al., 2000; McKiernan et al., 2000; Minton et al., 1998; Thio et al., 2001; Vejbaesya et al., 2000) . It has also been reported that the variation within HCV is predominantly independent of the host humoral response to HVR1 and may be the result of accumulating viral replication errors and the number of replication cycles (Allain et al., 2000) . Further studies, genetic and immunologic, of this unique patient population should help our understanding of the pathogenic mechanisms involved in chronic HCV infection.
MATERIALS AND METHODS
Samples
Eighteen patients were selected on the basis of the severity of liver disease, which was evaluated on biopsy using a modified Histological Activity Index (HAI) scoring system (Desmet et al., 1994) based on the Knodell system (Knodell et al., 1981) . All 18 are part of a cohort of 390 women who were recipients of an HCV (genotype 1b)-contaminated batch of anti-D administered in 1977-1978 which was prepared from one individual (index case) and have tested positive for HCV RNA. Liver biopsies were carried out on 363 of these women (Kenny-Walshe, 1999) . The serum samples were collected for this study in 1998-1999, and the 18 patients were included on the basis of successful PCR of both the E1/E2 and NS5b regions. None of these patients had any other risk factors for HCV infection. All were confirmed as having HCV infection by PCR amplification of the 5ЈUTR. Four of the patients, R35021, R35030, R35041, and R35076, had received interferon therapy prior to this study (1994) (1995) (1996) (1997) (1998) and were nonresponders. Twelve patients had either no or mild fibrosis (staging score of 0-1), while 6 had severe fibrosis or cirrhosis (staging score of 3-4) ( Table 3 ). In 1998, serum samples were also obtained from the original donor (staging score of 0) from whom the original anti-D product had been manufactured, making a total of 13 patients with no or mild disease. The nucleotide sequence of the index case had been previously reported (McAllister et al., 1998) . All studies were approved by the institutional review boards of the institutions involved.
RT-PCR
Viral RNA was extracted from l f serum with guanidine thiocyanate and phenol in a monophase solution (Tri Reagent BD, Sigma). Five microliters of the extracted RNA was used for cDNA synthesis with 10 U of reverse transcriptase (Promega) in 20 l of buffer (50 mM HCl, pH 8.0, 5 mM MgCl 2 , 5m M DTT, 50 mM KCl), 600 M dATP, dGTP, dTTP, dCTP, 1.5 m random primers, and 10 U RNasin. The E1/E2 fragment containing the HVR1 was amplified using nested primers S1 (nt 1338-1357; 5Ј CTACTCCGGATCCCACAAGC 3Ј) and S9 (nt 2039-2057; 5Ј TGTTGCCCGCCCTCCGATG 3Ј) for the first round of PCR and primers S3 (nt 1414-1432; 5Ј ATTCCATGGTGG-GAACTCG 3Ј) and S4 (nt 1848-1867; 5Ј GGGCTCGGAGT-GAAGCAATA 3Ј) for the nested reaction. The PCR reactions were carried out using a Perkin-Elmer Robocycler. Reaction conditions in the first round included 40 cycles at 94 o C for 1 min, 50 o C for 1.5 min, and 72 o C for 1.5 min; in the nested PCR they were 35 cycles at 94 o C for 1 min, 48 o C for 1 min, and 72 o C for 1 min. Each reaction was carried out with 0.4 U Taq DNA Polymerase (Promega) in 50 l of buffer (50 mM KCl, 10 mM Tris-HCl, pH 9.0, Triton X-100, 1.5 mM MgCl 2 ), 30 M each dATP, dGTP, dTTP, dCTP, and 0.25 M each outer primer. One microliter of this PCR reaction was added to 50 l of fresh reaction mix for the nested PCR. The NS5b region was amplified in a single round of amplification with primers NS5A (nt 8245-8262; 5Ј GATGGTAACGCAGTTCGG 3Ј) and NS5B (nt 8613-8630; 5Ј GCTACCGATTCGAGGAG 3Ј). The reaction conditions included 50 cycles at 94 o C for 45 s, 40 o C for 1 min, and 72 o C for 2 min.
Nucleotide sequence analysis
Each RT-PCR fragment was directly sequenced using a Perkin-Elmer 310 Genetic Analyzer. Unincorporated nucleotides and primers were removed from the amplified products with the Rapid Purification system (Boehringer Mannheim) and 100 ng of the DNA was added to 8 l of cycle sequencing ready reaction mix (PerkinElmer) and 3.2 pmol of primer in a total volume of 20 l for 25 cycles. The cycling sequencing conditions were 96 o C for 30 s, 50 o C for 30 s, and 60 o C for 4 min. The extension products were purified by ethanol precipitation at 4 o C for 15 min and centrifugation for 30 min. The pellet was resuspended in 25 l of template suppression reaction (Perkin-Elmer) and heated at 95 o C for 2 min. The sample was then loaded onto the 310 Genetic Analyzer.
Quasispecies analysis
The E1/E2 PCR products from four patients with mild disease (R35060, R35041, R35016, and R29217) and four patients with severe disease or cirrhosis (R35044, R35076, R34028, and R35047) were cloned into the pCRScript vector (pCR-Script Amp SK(ϩ) Cloning Kit, Invitrogen) following the manufacturer's protocol. Nine to 13 clones of each patient sample were sequenced for quasispecies analysis.
Compilation of sequence data
Part of the E1/E2 region, including the HVR1 (364 nucleotides) and NS5b (301 nucleotides), was chosen for analysis. Alignments were prepared for each region, HVRtot (anti-D and published unrelated E1/E2 sequences), HVRds (anti-D and published unrelated HCV1b E1/E2 sequences), and NS5tot (published unrelated and anti-D NS5b sequences). A fourth alignment (HVRquasi) was also prepared, which included all the quasispecies of the E1/E2 region from eight patients (R35060, R35041, R35016, R29217, R35044, R35076, R35028, and R35047) and the donor sequence.
Sequences from the EMBL database included in the HVRtot (genotype in parentheses) were D100749 (HCV1b), M62321 (HCV1a), D14853 (HCV1c), D00944 (HCV2a), D10988 (HCV2b), D50409 (HCV2c), D14311 (HCV3a), D26556 (HCV3b), Y11604 (HCV4a), and Y13184 (HCV5a). Sequences from the EMBL database included in the NS5tot are as above, except for D14311 and D50409, where there is no NS5 sequence available. The sequences from the EMBL database included in HVRds were (accession numbers are in parenthesis if different) HPCK1S1 (D50483), HPCK1R1 (D50480), HCU45476 Note. The first figure (inflammatory activity) in the HAI column represents a composite grading score out of a total of 18 (Knodell I-III), while the second figure represents a staging score from a total of 4 (Knodell IV). The staging score is based on the extent of fibrosis and the development of cirrhosis with 0, no fibrosis; 1, mild fibrosis; 2, moderate fibrosis; 3, severe fibrosis and 4, cirrhosis. R29217 is the 1998 sample from the donor from which the anti-D product was originally produced.
(U45476), AF073027, AF073038, AF073042, HCU45462 (U45462), AF056789, AF056792, AF056794, AF056790, AF056791, AF056745, AF056736, AF056748, AF056751, AF056752, AF054256, HPC5TRJ4 (D00832), HPCJ483 (D13558), D89815, AB014490, AB014489, HCU14235 (U14235), HCU37635 (U37635), HPCGENENTI (M84754), HPCHUMR (M58335), and HPCPEP68 (D00691). The accession numbers for the E1/E2 sequences from this study are HCR29217, HCR35010, HCR35016, HCR35021, HCR35025, HCR35024, HCR35027, HCR35028, HCR-35030, HCR35037, HCR35041, HCR35043, HCR35044, HCR35047, HCR35060, HCR35061, HCR35074, HCR-35076, and HCR35090; those for the E1/E2 quasispecies analysis are HCR3504701, HCR3504702, HCR3504704-08, HCR3504710-13, HCR3506001-09, HCR3506011-12, HCR3504101-03, HCR3504105-06, HCR3504108-11 HCR-350440101-02, HCR3504405-07, HCR3504411-14, HCR-3501601, HCR3501604-08, HCR3501610-13, HCR3502802, HCR3502806, HCR3502810-19, HCR3507601-13, HCR-2921702, HCR2921704-09, and HCR2921711; and those for the NS5b region are HCR29217N, HCR35010N,  HCR35016N, HCR35021N, HCR35025N, HCR35024N,  HCR35027N, HCR35028N, HCR35030N, HCR35037N,  HCR35041N, HCR35043N, HCR35044N, HCR35047N,  HCR35060N, HCR35061N, HCR35074N, HCR35076N , and HCR35090N
Phylogenetic analysis
The alignment of nucleotide sequences obtained in this study and unrelated sequences from the database was carried out by hand using MacClade version 3.05 (Maddison and Maddison, 1992) . The phylogenetic analysis was evaluated using TREE-PUZZLE 5.0 (Strimmer and Von Haeseler, 1997) and PAUP* version 4.0b8 (written by David L. Swofford). The REV model with ⌫-distributed rates across sites was used to estimate nucleotide distance matrices for the E1/E2 region for the HVR anti-D alignments and for the NS5b region for the NS5 anti-D alignments. The model was chosen as the best fitting HCV evolutionary model (Salemi and Vandamme, 2002) . All the relevant parameters of the model were also estimated with the maximum likelihood method implemented in PAUP* for each dataset. The phylogenetic trees for HVRtot, HVRds, and NS5tot were constructed using neighbor joining and maximum likelihood mplemented in PAUP* using the same models of nucleotide substitution as above. Bootstrap support for the internal branches of each tree was obtained by analyzing 1000 bootstrap replicates. Phylogenetic trees with the NJ method and the simple Jukes and Cantor model were also obtained for the HCV clones in the E1/E2 region from four patients with mild and four with severe liver disease or cirrhosis (see above). These trees were used as approximated trees to test for the best fitting nucleotide substitution model of the HCV quasispecies within infected individuals. Calculations were carried out with MODELTEST version 3.0 (written by David L. Posada).
Evolutionary rate analysis
The evolutionary rates (nucleotide substitutions/site/ year) of the E1/E2 nucleotide region of each patient were calculated individually by counting the total number of substitutions between the donor material (AF056736) and the current patient sequence.
Viral epidemiology signature pattern analysis
The viral epidemiology signature pattern analysis (VESPA) program (Korber and Myers, 1992) was employed to determine whether there were specific signature amino acid sequences which could be identified as being associated with or could differentiate between mild and severe disease. The sequences for the E1/E2 region were divided into two sets, one for those with mild disease and one for those with severe disease or cirrhosis, and aligned using MacClade. The VESPA program was also used to similarly analyze the predicted amino acid sequences present in the viral quasispecies.
